Bibliographie CANNABINOÏDES et Accidents de la route Docteur Christian SUEUR, GRECC, novembre 2018. ADLAF E.M., MANN R.E., PAGLIA A. : Drinking, cannabis use and driving among Ontario students, Canadian Medical Association Journal, 2003, 168, 565-566. : AHLNER J., HOLMGREN A., JONES A.W. : Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in Sweden, Scandinavian Journal of Public Health, 2013, PMID : 24265165. AITKEN C., KERGER M., CROFTS N. : Drivers Who Use Illicit Drugs : behaviour and perceived risks, Drugs : Education, Prevention and Policy, 2000, 7, 1, 39-50. Doi : 10.1080/dep.7.1.39.50 . ALVAREZ F.J., FIERRO I., Del [...]
Lire la suiteMedicinal cannabis - Potential Drug Interactions M.A. Alsherbiny, C. Guang Li, décembre 2018. www.preprints.org, doi:10.20944/preprints201812.0032.v1 https://www.researchgate.net/publication/329559938_Medicinal_Cannabis_-_Potential_Drug_Interactions Endocannabinoids system (ECS) engrossed a considerable interest as potential therapeutic targets in various carcinomas and cancer related conditions alongside with neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy induced nausea and vomiting (CINV). However, pharmacokinetics and pharmacodynamics interactions could be perceived in drug combinations, so in this short review we tried to shed the light over the potential drug interactions of medicinal cannabis. Hitherto, few data have been provided to the healthcare practitioners about [...]
Lire la suitePolitique en matière de drogue : le cannabis à usage médical en Europe Observatoire européen des drogues et toxicomanies, décembre 2018. POLITIQUE EN MATIÈRE DE DROGUE: LE CANNABIS À USAGE MEDICAL EN EUROPE L’Observatoire européen des drogues et des toxicomanies publie son premier rapport sur le cannabis à usage médical (4.12.2018, LISBONNE) Que disent les données scientifiquement validées à propos du cannabis et des cannabinoïdes à usage médical? Quelle est la différence entre les médicaments et les préparations à base de cannabis et pourquoi est-ce important? De quelle manière cette question est-elle réglementée dans l’Union européenne (UE)? Un nouveau rapport publié ce jour par l’Observatoire européen [...]
Lire la suiteLa Réduction des Méfaits de la Consommation de Cannabis à des Fins Non Médicales Association des Infirmières et Infirmiers du Canada, janvier 2018, 18 pp. Ottawa, Ontario, Canada. https://www.cna-aiic.ca/~/media/cna/page-content/pdf-fr/la-reduction-des-mefaits-de-la-consommation-de-cannabis-a-des-fins-non-medicales.pdf?la=fr
Lire la suiteLes méta-analyses et le cannabis, ou la négation du savoir clinique 21 Septembre 2011 Dr. Christian Sueur, Psychiatre, praticien hospitalier http://tdme.free.fr/?p=2730#annot8 A l’ère des méta-analyses, la clinique psychiatrique bat de l’aile…., Ce que l’on peut lire aujourd’hui sur les « dangers du cannabis » fournit un exemple étonnant de cette perte du savoir clinique. Et pourtant, bien des « méta-analystes » qui parfois, n’ont jamais vu un patient, sans vergogne, « disent le vrai », et emportent l’opinion avec eux, opinion et journalistes qui se font l’écho de ses assertions, sans même émettre la moindre critique vis-à-vis de ces « chiffres » érigés en « [...]
Lire la suiteAntidépresseur-like effect induced by Cannabidiol is dependent on brain serotonin levels. A.J. Sales, C. C. Crestani, F. S. Guimaraes, S. R.L. Joca, Progress in Neuropsychopharmacology & Biological Psychiatry, 2018 Aug 30; 86: 255-261. Doi: 10.1016/j.pnpbp.2018.06.002 https://www.ncbi.nlm.nih.gov/pubmed/29885468 PMID : 29885468 Abstract Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in [...]
Lire la suiteCannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal, F. Kamal, D. E. Lantela, Frontiers in Neuroscience, 2018, 12, article 730. https://doi.org/10.3389/fnins.2018.00730 Abstract : Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, [...]
Lire la suiteThe Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs, Chapter 5 S. Gaetani, P. Dipasquale, A. Romano, L. Righetti, T. Cassano, D. Piomelli, V. Cuomo, International Review of Neurobiology, 2009, 85, 57-72 DOI: 10.1016/S0074-7742(09)85005-8 https://www.researchgate.net/publication/26675793_Chapter_5_The_Endocannabinoid_System_as_A_Target_for_Novel_Anxiolytic_and_Antidepressant_Drugs I. The Endogenous Cannabinoid System II. Endocannabinoid Role in Emotional Reactivity and Mood Tone III. EVects of Exogenously Administered Cannabinoid Agonists and Antagonists IV. Enhancement of the Endogenous Cannabinoid Tone V. Faah-Knockout Phenotype VI. Conclusions References Observational studies in humans suggest that exposure to marijuana and other cannabis-derived drugs produces a wide range of subjective eVects on mood tone and emotionality. These observations have their counterpart in animal studies, showing that cannabinoid agonists strongly [...]
Lire la suiteThe endocannabinoid system as a target for novel anxiolytic drugs S. Patel, M.N. Hill, J.F. Cheer, C.T. Wotjak, A. Holmes, Neuroscience and Biobehavioral Reviews, 2017, 76, 56-66. https://doi.org/10.1016/j.neubiorev.2016.12.033 Abstract The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential ‘druggable’ targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifying eCBs recruitment by interfering with eCB-degradation, via fatty [...]
Lire la suiteAdverse effects of medical cannabinoids : a systematic review T. Wang, J-P. Collet, S. Shapiro, M.A. Ware, Canadian Medical Association Journal, 2008,178,13, 1669-1678 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/pdf/20080617s00017p1669.pdf Abstract Background : The therapeutic use of cannabis and cannabisbased medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods : We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated [...]
Lire la suite